HOME

Company

Science

Media

Investors

Careers

Contact

中
Home
Investors
IR Announcements
Jan 27, 2021
GenFleet Therapeutics Completes Series B+ Financing

January 27, 2021 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology, today announced the completion of its Series B+ financing worth hundreds of millions in RMB.
Mar 08, 2020
GenFleet Therapeutics Announces Series B Financing to Boost First-in-class Drug Development

March 8, 2020 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology, announced to have completed its series B financing led by CDH Investments and Shenzhen Capital Group.

Nov 30, 2018
GenFleet Therapeutics Closes Series A Financing to Advance Clinical Development of Small Molecules for Immuno-Oncology Therapeutics

November 30, 2018 (Shanghai, China) -- GenFleet Therapeutics recently announced the close of its series A financing worth 120 million yuan, which was led by Ally Bridge Group and participated by Sinopharm Capital and CSPC Pharma.